Goldman Sachs Alternatives completed the acquisition of a majority stake in Synthon from BC Partners.

Goldman Sachs Alternatives, a private equity firm, completed the acquisition of a majority stake in Synthon, a platform specialized in developing, manufacturing, and out-licensing complex generic medicines, from BC Partners, an investment firm. Financial terms were not disclosed. “The closing of this transaction marks an exciting new chapter for Synthon. We are proud of the momentum that we have built and are delighted to have Goldman Sachs Alternatives as our new partner. Working together, along with our more than 1,600 dedicated and talented colleagues around the world, I am excited about the next phase of our growth journey and look forward to maximizing patient impact by accelerating our growth, improving our operational network, and advancing our R&D platforms and capabilities for increasingly complex generics,” Anish Mehta, Synthon CEO.